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1990s, eosinophilic esophagitis (EoE) has emerged as a
commonly identified cause of esophageal symptoms in
children and adults.1,2 Although several highly effectively
dietary, pharmacologic, and endoscopic therapies have
been reported, none is currently approved by either the US
Food and Drug Administration (FDA) or European regula-
tory authorities. Evolving diagnostic criteria have chal-
lenged drug development, in particular the recognition of
complex interactions with the most prevalent esophageal
disorder, gastroesophageal reflux disease (GERD). Hetero-
geneity in the clinical presentations of affected children
and adults has created difficulties with uniform inclusion
criteria and the development of disease-specific, patient-
reported outcome (PRO) instruments. Furthermore,
controversies regarding the appropriate therapeutic end-
points of EoE have impeded the design of clinical trials.
Despite these obstacles, collaborative efforts by in-
vestigators, industry, the FDA, and patient advocacy groups
have resulted in substantial progress in drug development
in EoE over the past 2 decades.3 The purpose of this article
is to summarize discussions on EoE based on the 2016
Drug Development Conference sponsored by the Center for
Diagnostics and Therapeutics of the American Gastroen-
terological Association.
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The issue of how to differentiate EoE from GERD has
confounded clinicians and researchers alike, and anyone
attempting to design a clinical trial for EoE must confront
this problem. To fully appreciate the issue requires some
historical perspective. In 1982, it was reported that
eosinophils in the esophageal squamous epithelium
could be a manifestation of GERD.4 Pathologists rapidly
accepted this notion, and it became a common clinicalpractice for them to attribute esophageal eosinophilia to
GERD. The first report describing EoE as a unique, clin-
icopathologic syndrome distinct from GERD was pub-
lished in 1993.1 After that, clinicians slowly began to
appreciate that some patients who had esophageal
eosinophilia attributed to GERD, but who did not
respond to conventional GERD treatments, such as pro-
ton pump inhibitors (PPIs) and fundoplication, in fact
had EoE.5 As awareness of EoE grew, and physicians
learned that GERD and EoE could have very similar
clinical and histologic manifestations, much attention
focused on how to differentiate the 2 disorders.
Early on, a trial of PPI therapy seemed the most
logical and convenient means to differentiate GERD and
EoE.6 This practice was based on the assumption that
gastric acid inhibition was the only important action of
PPIs, and so only an acid-peptic disorder like GERD could
respond to them. Accordingly, in 2007, a consensus
report from the American Gastroenterological Associa-
tion Institute defined EoE as a primary clinicopathologic
disorder characterized by esophageal symptoms, esoph-
ageal biopsies showing 15 eosinophils per high-power
field, and the absence of pathologic GERD as evidenced
either by normal esophageal pH monitoring or lack of
response to PPIs.7 This definition implied that EoE and
GERD were mutually exclusive disorders that could be
distinguished by a trial of PPI therapy.
Soon after publication of the 2007 consensus report, it
became apparent that its definition of EoE would require
revision. Clinicians began to accept that patients could
have both EoE and GERD simultaneously, and plausible
reasons were proposed to consider that these disorders
might interact in such a way that one could contribute to
the development of the other.8 In response to these and
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to define EoE as “a chronic, immune/antigen-mediated
esophageal disease characterized clinically by symptoms
related to esophageal dysfunction and histologically by
eosinophil-predominant inflammation.”9 This definition
focused on what EoE was (an antigen-driven disorder)
rather than on what it was not (GERD).
The recent recognition of a condition called PPI-
responsive esophageal eosinophilia (PPI-REE) has added
yet another wrinkle to the GERD versus EoE saga.10
Patients with PPI-REE have typical EoE symptoms and
EoE esophageal histology, they do not have endoscopic
evidence of reflux esophagitis or abnormal esophageal acid
exposure bypHmonitoring, and theynevertheless exhibit a
clinical and histologic response to PPI therapy. Indeed,
studies have documented that 23%–61% of patients with
symptomatic esophageal eosinophilia respond to PPI
treatment.11 Early reports attributed PPI-REE to subclini-
cal GERD that responded to the acid-inhibitory effects of
PPIs. However, recent studies have shown that the clinical,
endoscopic, histologic, and esophageal gene expression
features of PPI-REE and EoE are virtually identical, and
multivariate analyses have not identified any feature that
can distinguish PPI-REE from EoE.12 Thus, PPI-REE re-
sembles EoE far more than it resembles GERD. Recent data
on the pathogenesis of EoE and GERD suggest how PPIs
might benefit both disorders.
The pathogenesis of EoE is thought to startwhen a food
antigen activates the immune system of a genetically
susceptible individual, causing naive CD4þ T cells to
differentiate into T-helper 2 (Th2) cells that secrete Th2
cytokines, such as interleukin (IL) 5 (important for
eosinophil production, activation, and recruitment), IL4,
and IL13 (which stimulate esophageal epithelial cells to
produce eotaxin-3, a potent eosinophil chemo-
attractant).13 In this way, a food triggers an allergic
response culminating in esophageal production of a che-
moattractant that draws activated eosinophils to the
esophagus, where they release noxious eosinophil secre-
tory products that cause esophageal symptoms, damage,
and remodeling. Recent studies suggest that the patho-
genesis of esophageal injury in GERD also is primarily
cytokine-mediated.14,15 Rather than the traditional notion
that refluxed acid causes a chemical injury that destroys
esophageal cells, these recent studies suggest that
esophageal damage in GERD is caused by inflammatory
cells attracted to the esophagus by cytokines produced by
esophageal epithelial cells when they are exposed to
refluxed acid and bile.
In vitro studies using esophageal epithelial cells in
culture have revealed anticytokine effects of PPIs that
could contribute to the healing of both GERD and EoE, and
that are entirely independent of effects on gastric acid
production. Omeprazole, in concentrations readily ach-
ieved in blood with conventional dosing, has been shown
to block eotaxin-3 secretion stimulated by Th2 cytokines
in esophageal epithelial cells from patients with EoE.16,17
Through this acid-independent, anti-inflammatory effectof blocking esophageal production of an eosinophil che-
moattractant, PPIs might decrease esophageal eosinophils
and symptoms in patients with EoE. In another series of
experiments, esophageal epithelial cells from patients
with GERDwere found to secrete IL8 (a major mediator of
inflammation) after exposure to acid and bile salts, an
effect that also was blocked by omeprazole.18 In addition
to the well-known acid-inhibitory effects of PPIs, this
acid-independent, anti-inflammatory PPI effect might
contribute to GERD healing.
At least 3 possible explanations for PPI-REE emerge
from these recent reports. First, patients with PPI-REE
might have subclinical GERD as the sole cause of their
esophageal eosinophilia, and their subclinical GERD re-
sponds to acid-inhibitory and, perhaps, anti-inflammatory
effects of PPIs. A second possibility is that patients with
PPI-REE have an antigen-driven esophageal eosinophilia
(ie, they have EoE) without GERD, and the antigen-driven
eosinophilia responds to PPI anti-inflammatory effects.
The recent description of patients with typical EoE signs
and symptomswho responded to a 6-food elimination diet
and to PPI therapy (administered at different times) pro-
vides some support for this mechanism.19 A third possi-
bility is that patients with PPI-REE have subclinical GERD
that is exacerbating or causing an antigen-driven esoph-
ageal eosinophilia, perhaps through GERD effects on
esophageal barrier function that render the epithelium
permeable to food antigens.20 Such patients might
respond to both the antisecretory and anti-inflammatory
effects of PPIs. Because the PPIs have multiple effects
that might benefit both EoE and GERD, a clinical and/or
histologic response to PPIs does not rule in GERD, and
should not rule out EoE.
The previously reviewed information suggests that the
current focus on how to distinguish EoE from GERDmight
be counterproductive, because the 2 diseases often coexist
with complex interactions. Even in the absence of GERD, it
seems clear that some patients who have an antigen-
driven esophageal eosinophilia can respond to PPI ther-
apy. Although the mechanisms underlying the response of
esophageal eosinophilia to PPIs remain unclear, it may be
counterproductive to limit the diagnosis of EoE only to
patients who fail to respond to PPIs. This practice creates
an artificial disease category (PPI-REE) that is excluded
from clinical trials and diverts attention from the primary,
antigen-driven disease process. A focus on elucidating
mechanisms whereby GERD can contribute to EoE path-
ogenesis might be more productive for achieving future
advances in the treatment of this allergic disorder.
Targeting Patient Populations in
Eosinophilic Esophagitis: Distinct
Concerns Confronting Drug
Development in Pediatrics
Several differences exist in how therapeutic success is
measured in children and adults during a clinical trial.
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diseases, the Pediatric Ulcerative Colitis Activity Index
was developed to account for school attendance, a factor
that may not be present in adults. Such is the case with
the current state of studying children and adults with
EoE, especially as it relates to symptom assessment. In
contrast to the relatively straightforward clinical pre-
sentation of adults with EoE, symptoms associated with
EoE in children can vary according to age, are nonspecific
in nature, and may be difficult to quantify.21
With respect to age, a young child may present with
feeding dysfunction, a school-age child with reflux-like
symptoms, and an adolescent with intermittent
dysphagia. Whether these symptoms are reported
differently by parents or patients may relate to devel-
opmental stage of the child, ability to cope with the un-
derlying problem, or lack or of recognition by parents
and family. For instance, a toddler may not be able to
report swallowing problems specifically but would
refuse to eat solids or not transition to more textured
foods. This could be viewed by a parent as a behavioral
problem as opposed to a manifestation of underlying
esophagitis.22 In contrast, an adolescent may report the
occurrence of solid food dysphagia with steak once a
month because of coping mechanisms of avoiding eating
steak, chewing food for long periods of time, or drinking
copious amounts of water. In the context of a clinical
trial, these symptoms may not occur regularly enough to
allow for a feasible clinical trial. In addition, these types
of differences may necessitate a variety of types of vali-
dated patient/proxy-reported outcome measures to
assess for therapeutic efficacy in young and older
children.
The lack of symptom specificity creates problems in
identifying children to target for enrollment and in
identifying best PROs to measure symptoms. As opposed
to adults who present with stereotypical features of solid
food dysphagia and food impaction, young children often
present with commonplace problems, such as feeding
problems, spitting up or vomiting, abdominal pain, or
symptoms that are only captured during thorough
review of symptoms because they are related to
coping.22 Feeding problems may be reported as refusal
to eat, disruptive mealtimes because of leaving the table,
prolonged meals, or lack of progression to more
advanced food textures or bite size. Reports of spitting
up or vomiting may be indistinguishable from what may
be reported with the more commonplace GERD.
Abdominal pain typically occurs in the upper abdomen
but is nonspecific. An astute physician may uncover
coping mechanisms, particularly in highly atopic patients
or those who have a family history of EoE, such as pro-
longed mealtimes caused by excessive chewing; avoiding
highly textured foods, such as rice, bread, and steak or
meats; or not eating at school or with friends because of
fear of embarrassment. Because these symptoms are
either very commonplace or may not be reported, tar-
geting enrollment can be difficult. In addition, the lack ofvalidated EoE PROs to measure these kinds of symptoms
has created a vacuum for monitoring therapeutic effi-
cacy. In fact, use of PROs developed for other diseases,
such as reflux, may not be appropriate for EoE. Recent
development of pediatric proxy and patient PROs spe-
cifically validated in pediatric EoE will clearly facilitate
this process.23–25
Once suspected patients are identified, clinical trials
may also be more complicated in children because of
the need to perform sedated endoscopy and biopsy to
assess for mucosal inflammation. Although an overall
safe procedure, endoscopic assessments in children
often require general anesthesia. Recent concerns have
been raised about the potential consequences of
repeated anesthetic exposures on the developing brain.
In addition, risks of sedation and the procedure itself,
time away from school for the patient and parent from
work, and the psychological effect of endoscopies on
children may make clinical trials in children more
challenging than adults.Treatment of Eosinophilic Esophagitis:
Current Status of Drug Development
Although several treatments have been shown to be
effective in EoE and are recommended in guidelines and
clinical algorithms,26 there are currently no FDA-
approved medications for EoE. Because of this, all
medications for this condition are presently being used
off-label. This leads to difficulty with obtaining insurance
coverage for medications and increased expense for
patients. Moreover, medication formulations designed
for airway indications are being suboptimally modified
for esophageal delivery in EoE.
The mainstay of EoE pharmacologic therapy, for
patients with esophageal eosinophilia who do not
respond to PPIs, are topical corticosteroids. These are
asthma preparations, such as fluticasone in a multidose
inhaler or slurry of aqueous budesonide that is
swallowed rather than inhaled to coat the esophagus.
The efficacy of these medications has been shown in
cohort studies,27–29 randomized trials,30–37 and several
meta-analyses.38–41 However, histologic nonresponse
rates range from 25%–50% in randomized clinical
trials,30,32–37 and can be higher than that in studies that
report “real world” rates.42,43 One likely explanation for
these high rates of nonresponse is that the topical
steroids used in EoE are not formulated for esophageal
deposition. Patients either have to coordinate puffing an
inhaler into their mouth during a breath hold before
swallowing a medication, or mix a thickened budesonide
solution themselves. Either option is not ideal and leads
to dosing and concentration inconsistencies. The impor-
tance of maximizing esophageal deposition was shown in
1 randomized trial where increased esophageal contact
time, regardless of the delivery mechanism, was associ-
ated with improved histologic response.36
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been 2 recent phase 2 trials studying novel steroids
specifically formulated to enhance esophageal deposi-
tion in EoE. In the first, 2 doses of a budesonide effer-
vescent tablet and a budesonide viscous suspension
were compared with placebo.44 Histologic response
rates ranged from 95%–100% for the topical steroids,
compared with 0% in placebo. Although endoscopic
severity was significantly decreased in the active
treatment arms, both the active and placebo groups had
a similar improvement in symptoms. In the second, a
budesonide oral suspension was compared with
placebo.45 Here, 39% in the budesonide arm had a
histologic response compared with 3% in placebo, but
there were associated symptomatic and endoscopic
improvements in these patients, measured for the first
time using validated instruments. Both of these agents
are currently in phase 3 trials and show the importance
of developing medications to maximize esophageal
deposition, but also of including specific study design
elements that enhance measurement of the primary
endpoints.
Until such new drugs are available, however, pa-
tients and physicians have reported several ways to
increase topical steroid esophageal deposition. For
budesonide, efficacy has now been reported for mixing a
slurry of aqueous budesonide with sucralose, elemental
formula, honey, maple syrup, agave nectar, rice cereal,
xanthan gum, and several other similar thickening
agents.43,46–48 It is also possible to order compounded
budesonide syrup from a specialized pharmacy. For
fluticasone, using the diskus device rather than the
multidose inhaler may be preferable. Inside the diskus
is a strand of blister packets containing powdered flu-
ticasone, which when opened, placed on the tongue, and
swallowed, also improve esophageal eosinophil
counts.49 Use of other topical steroids, including cicle-
sonide, which is a high-potency steroid prodrug that
must be activated by an epithelial esterase (present in
both the pulmonary and esophageal mucosa), has also
been reported.47,50,51
It is important to note that multiple other existing
pharmacologic treatment modalities have been assessed
forEoE. In general, these approaches are eithernot effective
or limited by side effects. These strategies include systemic
corticosteroids29,31,52; leukotriene antagonists50,53–56;
mast cell stabilizers54,57; immunomodulators58; and
biologics, such as anti-IgE and infliximab.59–61
With increasing knowledge of EoE pathogenesis,
however, there is significant interest in developing
treatments targeting the underlying physiology of EoE.
The anti-IL5 medications were the first such agents
tested in EoE, and there has been 1 small randomized
trial in adults and 2 larger ones in children.62–64
Although these agents resulted in a moderate decrease
in esophageal eosinophilia, symptoms improved simi-
larly in the placebo and active treatment arms in the 2
larger trials. Although in retrospect this lack of symptombenefit was likely caused by the use of nonvalidated
instruments and other study design elements (see later),
these medications are not currently being pursued
for approval in EoE. However, both medications (mepo-
lizumab and reslizumab) have been recently approved
for treatment of eosinophilic asthma; use in EoE would
be considered off-label.
Recently, there have been promising data regarding
anti-IL13 medications. This class was first reported in a
small randomized controlled trial, and showed efficacy
for reducing esophageal eosinophil counts.65 Phase 2
data from a different anti-IL13 antibody were recently
presented.66 In this randomized controlled trial, the
medication significantly and markedly decreased eosin-
ophil counts compared with placebo, significantly
improved endoscopic severity, and there was also a
strong trend toward symptom improvement.
In addition to these drugs, there are other studies
listed on clinicaltrials.gov exploring novel agents in EoE.
For example, an anti-IL4 antibody, dupilumab, is
currently in phase 2 testing. Immunosuppressants
(sirolimus) and a transforming growth factor-b inhibitor
(losartan) are in proof-of-principle testing. A small
molecule, which is an antagonist to the chemoattractant
receptor-homologous molecule expressed on Th2 cells
and blocks binding of prostaglandin D2, has also shown
promise.67
In summary, there are huge needs related to phar-
macologic therapy of EoE. There are no FDA-approved
medications, no available medications are formulated
for esophageal deposition or target EoE pathogenesis,
and nonresponse to primary and secondary treatments is
common. However, there are also huge opportunities for
drug development in EoE. Multiple new medications are
under study, including novel topical steroid formula-
tions, novel biologics, and novel small molecules. With
the development of new validated outcome measures for
EoE and incorporating specific clinical trial design
elements, there is a higher likelihood of identifying
effective medications.Clinical Trial Design in Eosinophilic
Esophagitis: Defining Endpoints
Identification of appropriate therapeutic endpoints is
of central importance to clinical practice, investigator
studies, and pharmaceutical trials. The ideal endpoints of
therapy in EoE should be associated with a clinically
meaningful reduction in symptoms, normalization of
quality of life, resolution of esophageal inflammation,
reversal of existing disease complications, and preven-
tion of future complications.68 In clinical practice, man-
agement decisions in EoE are often based on patient
symptoms, whereas in clinical trials, histopathology as
assessed by esophageal mucosal eosinophil density, is a
primary determinant of efficacy. Current pharmaceutical
trials being reviewed by the FDA are using the coprimary
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inflammation. Additional endpoints of endoscopic
activity and novel biomarkers of disease activity and
pathogenesis are under development.Symptom Endpoints
Initial investigator-initiated clinical studies in pedi-
atric and adult EoE used “home grown” symptom
assessment tools, physician or patient global assessment
metrics, or dysphagia instruments previously validated
in non-EoE cohorts. Over the past 5 years, several PRO
instruments have been developed and validated for
evaluation of symptoms and quality of life in both pedi-
atric and adult EoE (Table 1). The Daily Symptom
Questionnaire was developed and validated in the
context of a pharmaceutical phase 2 study of budesonide
oral suspension.69 At the time of the design of this study,
a validated PRO did not exist for assessment of
dysphagia in EoE. The items of the Daily Symptom
Questionnaire were developed based on patient focus
groups to assess the frequency and intensity of
dysphagia. Responsiveness to change in the context of a
placebo-controlled trial of budesonide oral suspension
demonstrated the ability of the instrument to detect
change in symptom activity.45 A second PRO instrument,
the EoE Activity Index, was developed and validated for
use in adults by an international collaboration led by a
Swiss group.70 In addition to questions about the fre-
quency and intensity of dysphagia, the EoE Activity Index
incorporated a novel, “visual dysphagia questionnaire”
that asks patients about food avoidance and modification
behaviors. The visual dysphagia questionnaire specif-
ically takes into account that patients may not report
dysphagia due to avoidance of harder texture foods such
as meat or bread. In addition, slower eating patterns or
modification of food particle size or consistency prior to
ingestion are assessed to capture a more comprehensive
view of dysphagia severity. A pediatric symptom
assessment tool has been validated but not yet evaluated
in terms of responsiveness to therapy.23 Furthermore,
quality-of-life instruments have been developed andTable 1. Patient-Reported Outcome Instruments for Children
and Adults With EoE
Symptom scoring tool98
Dysphagia Assessment Tool34
Physician global assessment
Patient global assessment
Mayo Dysphagia Questionnaire
EoE Quality of life in adultsa71
Dysphagia Symptom Questionnairea69
Pediatric EoE Symptom Severitya23
Pediatric quality of lifea24
EoE Activity Indexa70
aValidation in EoE.validated for children and adults with EoE but perfor-
mance in terms of responsiveness the therapy are still
being evaluated.24,71,72
Although symptom assessment is a logical endpoint for
trials in EoE, it is important to appreciate limitations to
this outcomemetric (Table 2). Symptoms of dysphagia are
highly dependent on eating behaviors. Careful mastica-
tion, prolonged meal times, and food avoidance can
circumvent dysphagia and lead to inaccurate assessment
of disease activity. Even with incorporation of the visual
dysphagia questionnaire, the EoE Activity Index was
shown to have only modest detection of inflammatory or
endoscopic activity.73,74 Another major conceptual
concern with overreliance on symptom outcomes is the
relationship between symptoms and esophageal remod-
eling. Remodeling in the formof esophageal strictures, and
not mucosal inflammation, is the major determinant of
symptom outcomes of food impaction.75,76 The current
understanding of the pathogenesis and natural history of
EoE posits esophageal remodeling as a long-terms
consequence of esophageal inflammation.77 Fibroste-
notic strictures seem to have limited reversibility with
therapeutics directed at the inflammatory response. Thus,
holding anti-inflammatory therapies to the “high bar” of
symptom improvementmay overlook potential benefits of
such therapies in preventing disease remodeling conse-
quences. This view is supported by the clinical observa-
tion that symptoms of dysphagia can be effectively
ameliorated inmore than 90%of patientswith esophageal
dilation, without altering the underlying inflammatory
response.78 Similarly symptoms may persist in the setting
of fibrotic strictures, in spite of normalization of mucosal
inflammation. Other practical limitations of symptom
assessment in clinical trials include the sporadic nature of
dysphagia events that may not be captured with short-
duration assessment windows and a substantial placebo
effect that can make detection of meaningful symptom
improvement challenging.45Histologic Endpoints
Histologic assessment by means of eosinophil density
is the most commonly used primary endpoint in current
clinical trials in EoE (Table 2). The response is most
commonly defined by a reduction in tissue eosinophilia.
However, the optimal degree of reduction is poorly
defined such that a variety of endpoints have been used
including thresholds of <15, <10, <6, and <5 eosino-
phils per high-power field. Variations in the cross-
sectional area of different microscope manufacturers is
a concern when comparing values across different
studies but this limitation can be corrected by normal-
izing density to eosinophils per mm2.44,79 Most clinical
trials have used a central, blinded pathologist to improve
consistency. The calculation of peak eosinophil counts
can be based on sampling of multiple levels of the
esophagus or the mean of multiple high-power fields
Table 2. Advantages and Disadvantages of Therapeutic Endpoints in EoE
Endpoint Advantages Disadvantages
Symptoms Addresses FDA guidance regarding patient
perspective, intrinsic to disease definition,
validation of specific PROs
Dependent on eating behavior and food modification,
sporadic basis of complaints, differences in
pediatric and adult symptoms, association with
esophageal remodeling rather than inflammation,
placebo response
Eosinophil density
(eosinophils/high-
power field;
eosinophils/mm2)
Objective biomarker, highly reproducible, intrinsic to
disease definition, applicable to both children and
adults, responsiveness in placebo-controlled trials
Limited correlation with symptoms, heterogeneity in
methods to quantify, threshold to define response
not established, tissue sampling variability,
incomplete measure of disease activity
Endoscopic features
(EREFS)89
Objective measure, moderate-good interobserver
agreement, responsiveness in placebo-controlled
trials, measures “whole organ” activity, correlation
with disease activity, applicable to both children
and adults
Variability in prevalence of individual features, limited
correlation with eosinophil density, threshold to
define response not established
Quality of life24,25,71 Addresses FDA guidance regarding patient
perspective, pediatric and adult instruments
validated
Responsiveness to therapy not established, threshold
to define response not yet defined, limited
correlation with eosinophil density, not able to be
used as a clinical trial primary endpoint
Comprehensive histologic
assessment
(composite index of
multiple histologic
parameters)80
Addresses concerns of overreliance on eosinophil
density, applicable to both children and adults
Limited validation, responsiveness to therapy not
established, variability in prevalence of individual
features, reliance on tissue orientation
Esophageal distensibility
(radiologic assessment
or impedance
planimetry)76,96
Objective measure of esophageal remodeling,
correlation with symptom outcomes
Impedance planimetry not widely available, automated
analyses under development, responsiveness to
therapy not established
Gene expression95 Comprehensive assessment of multiple factors
involved in pathogenesis
Clinical relevance of molecular readout not
established, advantages over eosinophil density
not established
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studies have reported endpoints based on a percentage
reduction in eosinophilia (ie, >50%, >90%) or mean
eosinophil densities for a cohort.32 Overlooked markers,
such as expression of eosinophil activation products,
basal cell hyperplasia, spongiosis, subepithelial fibrosis,
lymphocytes, or mast cell infiltration, may be as relevant
as the actual number of eosinophils. The recent devel-
opment of an EoE Histologic Severity Score has included
several of these additional pathologic parameters to
provide a more comprehensive and hopefully more ac-
curate characterization of mucosal inflammation in EoE
for clinical trials.80 However, histologic improvement of
mucosal inflammation could be misleading as an indi-
cator of overall disease activity. Studies have demon-
strated that esophageal eosinophilia can extend to
involve the submucosa and muscularis layers that are
not sampled by esophageal mucosal biopsies.59,81–83
Pediatric and adult studies in EoE using endoscopic ul-
trasonography revealed significant expansion of the
esophageal wall and the individual layers including the
mucosa, submucosa, and muscularis propria compared
with healthy control subjects.83,84
Advantages of histologic assessment of EoE activity
using esophageal mucosal eosinophil density include that
it is an objective and quantifiable measure with a highdegree of interobserver agreement.85 Controlled trials
have demonstrated a very low placebo response for
eosinophil density over 2-to-16-week study periods.
Reduction in eosinophil density has generally tracked
with improvement symptom and endoscopic outcomes,
although the degree of concordance has been variable
and limited across trials.38,74
Problems with the use of eosinophil density as the
primary outcome of EoE trials are based on the limited
correlation with symptom outcomes.74,86 This observa-
tion has led to concerns that other markers of inflam-
mation other than eosinophil density may be factors in
disease activity and progression.80 Eosinophil degranu-
lation proteins including eosinophil-derived neurotoxin,
eosinophil peroxidase, and eosinophil cationic protein
may identify eosinophil activity that may be as relevant a
metric as eosinophil density.80,87 Additional inflamma-
tory cells, such as lymphocytes, basophils, and mast cells,
have defined roles in the allergic and Th2 pathogenesis
of EoE and are not captured with the current focus on
eosinophil density.88 Eosinophil quantification in the
esophageal mucosa does not evaluate subepithelial
remodeling that has been associated with adverse
symptom outcomes. Use of the Histologic Severity Score
may provide a more comprehensive assessment of
mucosal inflammation. Further studies linking eosinophil
August 2017 Eosinophilic Esophagitis 1179density with disease progression will also substantiate
the current reliance of this biomarker as a primary
endpoint.Endoscopic Outcomes
The EoE Endoscopic Reference Scoring system
(EREFS) is a classification and grading system designed
to standardize nomenclature for the major endoscopi-
cally identified, esophageal features of EoE (edema, rings,
exudates, furrows, and strictures).89 Studies from the
United States and Europe have demonstrated moderate
to good interobserver and intraobserver agreement
using EREFS.89,90 Kappa scores for interobserver agree-
ment exceeded that of the LA classification system for
GERD. Prospective use of the EREFS system has identi-
fied endoscopic detection of esophageal abnormalities in
more than 95% of patients with EoE.45,91 Recent studies
have demonstrated the clinical relevance of endoscopic
severity assessment in EoE. The severity of each of the
EREFS subscores was associated with patient-reported
global symptom activity.70 Food impaction risk and
esophageal mural distensibility was also significantly
associated with EREFS ring severity.92 Moreover, physi-
cians’ global assessment of disease activity is largely
based on endoscopic findings, rather than severity of
histopathology.73
A recent study demonstrated that the EREFS score
had a high degree of accuracy for diagnosis of EoE and
significant responsiveness to treatment.93 This study
prospectively evaluated patients with EoE who were
treated with either topical steroids or dietary elimina-
tion and compared their endoscopic findings with con-
trol subjects without EoE. EREFS correctly identified
patients with EoE with a high degree of accuracy, with
an area under the receiver operator characteristic curve
of 0.934, sensitivity of 88%, specificity of 92%, positive
predictive value of 84%, and negative predictive value
of 94%. Another recent study was the first randomized,
placebo-controlled trial to incorporate endoscopic out-
comes determined by EREFS.45 In this study, EREFS
scores significantly improved after treatment with
budesonide oral suspension and remained unchanged
with placebo. Each of the individual EREFS subscores
(ie, edema, rings, exudate, furrows) significantly
improved as did overall scores for the proximal and
distal esophagus.
In summary, a growing body of literature supports
the validity of systematic evaluation of endoscopic fea-
tures, as measured by the EREFS, with a promising role
as treatment endpoint in clinical practice and therapeutic
trials (Table 2).91 The ability of medical and diet thera-
pies to significantly improve endoscopically visible
esophageal inflammatory and structural alterations
substantiates the improvements in symptoms and his-
topathology. The emerging role of endoscopic assess-
ment in EoE has noteworthy parallels with the emphasison endoscopic mucosal healing as a primary endpoint of
therapeutics in inflammatory bowel disease and GERD.Future Endpoints
Biomarkers of EoE disease activity beyond symptoms
and mucosal healing are being actively evaluated. mRNA
expression provides a molecular fingerprint of key
upregulated and downregulated genes in esophageal bi-
opsies of EoE that is distinct from the signature identi-
fied in control subjects and patients with GERD.94,95 The
selection of a subset of 96 genes signature profile termed
the Eosinophil Diagnostic Panel includes clusters of
genes that depict the Th2 inflammatory response, mast
cell activation, and fibrosis pathways. Reversal of the EoE
pattern has been demonstrated in the setting of ran-
domized controlled trials using both topical fluticasone
in children and anti-IL13 therapy in an adult study.33,65
In addition to providing a biomarker panel for disease
activity, the Eosinophil Diagnostic Panel offers potential
for examining molecular pathways that may provide in-
sights into the pathogenesis and inform a personalized
approach to the therapy of EoE.
At the other end of the spectrum, end organ assess-
ment of esophageal remodeling of EoE is being evaluated
with the functional lumen imaging probe (FLIP). FLIP is a
catheter-based technology that provides information
about the biomechanical properties of the esophagus.
The device uses impedance planimetry to provide
detailed measurement of the esophageal wall cross-
sectional area in response to incremental pressure us-
ing controlled, volumetric distention. In an initial study,
FLIP demonstrated a 50% reduction in esophageal
distensibility in EoE compared with control subjects
using a metric defined as the distention plateau (cross-
sectional area or diameter at which incremental pressure
yields minimal changes in diameter).96 In a follow-up
study, the distention plateau was shown to be signifi-
cantly reduced in patients with EoE with adverse out-
comes of food impaction.76 Thus FLIP may provide a
quantitative measure of esophageal remodeling in EoE
that is a major determinant of symptom outcomes. As
such, FLIP may be a clinically relevant biomarker of
remodeling that complements the use of mucosal
inflammation endpoints.97 The use of FLIP to measure
esophageal distensibility is being examined as a sec-
ondary endpoint of therapeutic trials in EoE.Conclusions
The past 2 decades have witnessed remarkable
progress in the development of pharmacologic therapies
in EoE. Clinical and translational research has refined the
diagnostic criteria and continued to validate disease-
specific, PRO instruments. Unique biomarkers that
address the immunologic basis and remodeling
1180 Hirano et al Clinical Gastroenterology and Hepatology Vol. 15, No. 8consequences of EoE are being established as novel
endpoints of disease activity while providing valuable
insights into pathogenesis. Investigator- and industry-
sponsored clinical trials have paved the way for appro-
priate study design in EoE. The field has evolved from
case series to randomized, controlled trials of topical
steroids optimized for esophageal delivery and targeted
biologic therapies that address the immunologic un-
derpinnings of the newest esophageal disease. Ongoing
collaborative engagement of clinicians, investigators, in-
dustry, the FDA, and patient advocacy groups is essential
for continued progress in therapeutics in this relatively
new yet rapidly growing esophageal disease.References
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